3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
6
Urinary Bladder Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Gastrointestinal Neoplasms
1
Gastric or Gastroesophageal Cancer
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
8
Pemetrexed
8
capmatinib
7
Carboplatin
7
ceritinib
5
Cisplatin
5
Bevacizumab
4
Docetaxel
3
trametinib
2
motexafin gadolinium
2
aldesleukin
2
Vinorelbine
2
Paclitaxel
2
Interleukin-2
2
Gefitinib
2
BID protein, human
2
technetium 99m etarfolatide
1
spartalizumab
1
sintilimab
1
satraplatin
1
ribociclib
1
picropodophyllin
1
nazartinib
1
naporafenib
1
milademetan
1
lazertinib
1
fludarabine phosphate
1
fludarabine
1
farletuzumab
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma of Lung
×
bemarituzumab
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled